{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:45:51Z","timestamp":1785883551800,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004854","name":"St. Antonius Ziekenhuis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023976","name":"Zorgverzekeraars Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023976","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.msard.2026.107268","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:18:15Z","timestamp":1779549495000},"page":"107268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-539X","authenticated-orcid":false,"given":"P.C.G.","family":"Molenaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.J.","family":"Arnoldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.C.","family":"Beenakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.M.","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.J.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Heersema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hoitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Kragt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.P.","family":"van Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.W.J.M.","family":"Snoeijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.H.A.","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.G.","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.K.","family":"de Beukelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.F.","family":"Kalkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2026.107268_bib0019","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","article-title":"Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"37","author":"Bowen","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat. Sci."},{"issue":"8","key":"10.1016\/j.msard.2026.107268_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107268_bib0002","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp-2017-317509","article-title":"Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?","volume":"89","author":"Cerqueira","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"10076","key":"10.1016\/j.msard.2026.107268_bib0001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107268_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107268_bib0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with Rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol. Ther."},{"issue":"10","key":"10.1016\/j.msard.2026.107268_bib0007","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107268_bib0031","article-title":"Rituximab for people with multiple sclerosis","volume":"3","author":"Filippini","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.msard.2026.107268_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12883-022-02738-7","article-title":"Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis","volume":"22","author":"Fox","year":"2022","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.107268_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241239740","article-title":"Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry","volume":"17","author":"Frahm","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107268_bib0021","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40801-023-00387-x","article-title":"Treatment patterns by race and ethnicity in newly diagnosed persons with multiple sclerosis","volume":"10","author":"Geiger","year":"2023","journal-title":"Drugs Real. World Outcomes."},{"issue":"3","key":"10.1016\/j.msard.2026.107268_bib0011","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of Rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107268_bib0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107268_bib0025","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of Multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107268_bib0016","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","article-title":"Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020","volume":"80","author":"Henderson","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107268_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.647811","article-title":"Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network","volume":"12","author":"Hillert","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107268_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105851","article-title":"A personalized approach for anti-CD20 therapies in multiple sclerosis","volume":"91","author":"Hogenboom","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0032","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-023-11943-4","article-title":"Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension","volume":"271","author":"Kappos","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0028","article-title":"Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: a register-based prospective cohort study in Sweden","volume":"8","author":"Karampampa","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2026.107268_bib0037","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/ijerph19042203","article-title":"Adherence to therapy in patients with multiple sclerosis-review","volume":"19","author":"Koltuniuk","year":"2022","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"10.1016\/j.msard.2026.107268_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106207","article-title":"Prevalence and incidence of multiple sclerosis in the Netherlands","volume":"93","author":"Lemmens","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107268_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105638","article-title":"Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian multiple sclerosis and related disorders register","volume":"87","author":"Lepore","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107268_bib0006","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2026.107268_bib0009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14737175.2023.2208347","article-title":"The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis","volume":"23","author":"Morgan","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2026.107268_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231198963","article-title":"The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe","volume":"16","author":"Nicholas","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107268_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107268_bib0010","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2026.107268_bib0003","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107268_bib0036","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1186\/s12913-021-07012-z","article-title":"Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study","volume":"21","author":"Sippel","year":"2021","journal-title":"BMC. Health Serv. Res."},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0033","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/13524585221109386","article-title":"Should anti-CD20 be used as an immune reconstitution therapy?","volume":"29","author":"Smets","year":"2023","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2026.107268_bib0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective Treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107268_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233044","article-title":"Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations","volume":"17","author":"Stahmann","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.107268_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16289","article-title":"Real-world persistence of multiple sclerosis disease-modifying therapies","volume":"31","author":"Tallantyre","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107268_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:58:23Z","timestamp":1785880703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S2211034826003044"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107268","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107268"}}